Table 4.
Multivariate analysis of correlation between angptl3 and HDL components in the study subjects
| Controls vs. T2DM | Female controls | Female T2DM | Male controls | Male T2DM |
|---|---|---|---|---|
| Estimate (95 % CI) | Estimate (95 % CI) | Estimate (95 % CI) | Estimate (95 % CI)p | |
| N in category | 149 | 150 | 149 | 150 |
| HDL components | ||||
| Cholesterol (mg/dL) | 2.57 (0.48 to 4.65)* | 1.69 (0.13 to 3.25)* | 2.07 (0.14 to 4.00)* | 4.36 (2.08 to 6.64)ł |
| ApoA-I (μg/mL) | 1.14 (0.88 to 1.40)§ | 1.25 (0.87 to 1.63)§ | −0.03 (−0.42, 0.36) | 0.38 (−0.02 to 0.78) |
| Serum amyloid A(μg/L) | −47.07 (−89.60 to −4.53)* | −11.7 (−43.15 to 66.57) | −14.19 (−53.93 to 25.56) | −6.16 (−50.99 to 38.66) |
| Triglyceride (log, mg/dL) | 1.00 (0.93 to 1.08) | 1.00 (0.93 to 1.07) | 1.03 (0.97 to 1.09) | 1.12 (1.04 to 1.20)* |
| Phospholipid (pg/mL) | −5.96 (−74.81 to 62.89) | −37.24 (−91.14 to 16.66) | −54.71 (−127.59 to 18.18) | 83.09 (15.18 to 151.00)* |
| Sphingosine-1-phosphate (nmol/L) | −14.33 (−88.89 to 60.24) | −124.3 (−0.64 to 249.30) | −28.02 (−106.40 to 50.37) | 16.94 (−84.79 to 118.67) |
All associations were adjusted for age, body mass index and lipid lowering drugs (Statins and Niacin). Estimates given with 95 % CI express the difference in HDL components associated with 1-SD increase of ANGPTL3
Significance: § p < 0.0001; ł p < 0.01; * p < 0.05